Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANG046
MIFTS: 47

Angioimmunoblastic T-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

About this section

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 53 59 55
Immunoblastic Lymphadenopathy 53 59
T-Cell Lymphoma, Aild Type 53 59
Lymphogranulomatosis X 53 59
Angioimmunoblastic Lymphadenopathy 73
Aitl 53
Ailt 59

Characteristics:

Orphanet epidemiological data:

59
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0111147
ICD10 33 C86.5
Orphanet 59 ORPHA86886
UMLS via Orphanet 74 C0020981
ICD10 via Orphanet 34 C86.5
UMLS 73 C0020981
Sources

Summaries for Angioimmunoblastic T-Cell Lymphoma

About this section
Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to diffuse large b-cell lymphoma and follicular lymphoma, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are MECP2 and Associated Rett Syndrome and B Cell Development Pathways. The drugs Beleodaq and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotype is immune system.

Wikipedia : 76 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Sources

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

About this section

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 30.1 BCL6 MME
2 follicular lymphoma 29.7 BCL6 MME
3 peripheral t-cell lymphoma 28.9 BCL6 CXCL13 ITK MME
4 angioimmunoblastic lymphadenopathy with dysproteinemia 11.6
5 lymphoma 11.2
6 b-cell lymphomas 10.6
7 autoimmune lymphoproliferative syndrome, type v 10.3
8 leukemia 10.3
9 pure red-cell aplasia 10.2
10 pneumonia 10.2
11 vasculitis 10.2
12 plasma cell leukemia 10.2
13 gallbladder lymphoma 10.1 BCL6 MME
14 heart lymphoma 10.1 BCL6 MME
15 intravascular large b-cell lymphoma 10.1 BCL6 MME
16 spondyloarthropathy 1 10.1
17 leukemia, chronic lymphocytic 2 10.1
18 leukemia, chronic lymphocytic 10.1
19 mycosis fungoides 10.1
20 myelofibrosis 10.1
21 polyarteritis nodosa, childhood-onset 10.1
22 arthritis 10.1
23 hematopoietic stem cell transplantation 10.1
24 thrombocytopenia 10.1
25 cardiac tamponade 10.1
26 cervicitis 10.1
27 spondylitis 10.1
28 polyarteritis nodosa 10.1
29 hypereosinophilic syndrome 10.1
30 leukemia, b-cell, chronic 10.1
31 endotheliitis 10.1
32 methotrexate-associated lymphoproliferative disorders 10.1
33 testicular lymphoma 10.1 BCL6 MME
34 t-cell/histiocyte rich large b cell lymphoma 10.0 BCL6 MME
35 marginal zone b-cell lymphoma 9.9 BCL6 MME
36 breast papillary carcinoma 9.9 IDH2 MME
37 folic acid deficiency anemia 9.9 MME TET2
38 systemic lupus erythematosus 9.9
39 rheumatoid arthritis 9.9
40 scleroderma, familial progressive 9.9
41 anemia, autoimmune hemolytic 9.9
42 ascites, chylous 9.9
43 lymphoma, hodgkin, classic 9.9
44 wegener granulomatosis 9.9
45 follicular lymphoma 1 9.9
46 aspergillosis 9.9
47 membranous nephropathy 9.9
48 adult t-cell leukemia 9.9
49 anaplastic large cell lymphoma 9.9
50 chronic myelomonocytic leukemia 9.9

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma
Sources

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

About this section

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.1 BCL6 CXCL13 ITK MAF MME TET2
Sources

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 343)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
6
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Ifosfamide Approved Phase 4,Phase 1,Phase 2 3778-73-2 3690
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
11
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
12
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 51-75-2 4033
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 31703
16
Pirarubicin Investigational Phase 4 72496-41-4
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 BB 1101 Phase 4,Phase 3,Phase 2
27 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
28 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
29 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34
Isophosphamide mustard Phase 4,Phase 1,Phase 2 0
35 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Folate Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44
alemtuzumab Approved, Investigational Phase 3,Phase 1,Phase 2 216503-57-0
45
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
46
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
47
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
48
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
49
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
50
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
4 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
14 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
15 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
16 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
17 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
18 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
20 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
21 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
22 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
23 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
24 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
25 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
26 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
27 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
28 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
29 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymp Completed NCT02273739 Phase 1, Phase 2 AG-221
30 A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
31 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
32 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
33 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
34 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
35 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
36 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
37 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
38 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
39 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
40 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine
41 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
42 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
43 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
44 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
45 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
46 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
47 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
48 Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate
49 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Completed NCT00436618 Phase 2 Everolimus
50 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Sources

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

About this section
Sources

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

About this section

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

41
T Cells, Bone, Bone Marrow, B Cells, Lymph Node, Endothelial, Liver
Sources

Publications for Angioimmunoblastic T-Cell Lymphoma

About this section

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 345)
# Title Authors Year
1
Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. ( 29493850 )
2018
2
A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma. ( 29048103 )
2018
3
Epstein-Barr virus clonality and plasmacytosis in a patient with atypical angioimmunoblastic T cell lymphoma. ( 29189897 )
2018
4
Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. ( 29339730 )
2018
5
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
6
Florid Plasmacytosis in Angioimmunoblastic T Cell Lymphoma: A Diagnostic Conundrum. ( 29398831 )
2018
7
Hypercalcemia as a rare presentation of angioimmunoblastic T cell lymphoma: a case report. ( 29673407 )
2018
8
Secondary Cutaneous Epstein-Barr Virus-associated Diffuse Large B-cell Lymphoma with Hodgkin/Reed-Sternberg-like Cells in a Patient with Angioimmunoblastic T-cell Lymphoma. ( 29956714 )
2018
9
Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. ( 29909754 )
2018
10
The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH. ( 29621877 )
2018
11
Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. ( 29428971 )
2018
12
Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review. ( 29480865 )
2018
13
Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. ( 29197996 )
2018
14
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2018
15
Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma. ( 29636953 )
2018
16
Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. ( 29662631 )
2018
17
Angioimmunoblastic T Cell lymphoma mimics reactive lymphoid tissue on cytomorphology: A multimodality approach utilising cytology, immunocytochemistry and flow cytometry to resolve this diagnostic dilemma. ( 28370552 )
2017
18
Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. ( 28148900 )
2017
19
A review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. ( 28889481 )
2017
20
Angioimmunoblastic T-Cell Lymphoma. ( 28340875 )
2017
21
Two cases of angioimmunoblastic T-cell lymphoma with concomitant positive serology for acute Epstein-Barr virus infection. ( 29071053 )
2017
22
Invasive aspergillosis in Refractory Angioimmunoblastic T cell lymphoma. ( 29129826 )
2017
23
Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor. ( 28953629 )
2017
24
A Rare Case of Angioimmunoblastic T-Cell Lymphoma with Epstein-Barr Virus-Negative Reed-Sternberg-Like B-Cells, Chylous Ascites, and Chylothorax. ( 28487786 )
2017
25
TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. ( 28337768 )
2017
26
Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. ( 28194275 )
2017
27
Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. ( 28543514 )
2017
28
Cardiac Tamponade as Initial Presentation of Angioimmunoblastic T-Cell Lymphoma. ( 28481741 )
2017
29
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy. ( 28050005 )
2017
30
Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. ( 28832024 )
2017
31
Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. ( 28634614 )
2017
32
Angioimmunoblastic T-Cell Lymphoma: A Questionable Association with Follicular Dendritic Cell Sarcoma. ( 28197348 )
2017
33
Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). ( 28611626 )
2017
34
Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma. ( 28943543 )
2017
35
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. ( 29100307 )
2017
36
Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. ( 29279549 )
2017
37
Death caused by possible unrecognized (too Late Recognized) Mycobacterium gordonae infection in a patient with angioimmunoblastic T-cell lymphoma. ( 28559527 )
2017
38
Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas. ( 28945625 )
2017
39
Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report. ( 28885361 )
2017
40
Image Gallery: Generalized annular figurate erythema as an unusual presentation of angioimmunoblastic T-cell lymphoma. ( 28940282 )
2017
41
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. ( 28082343 )
2017
42
Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. ( 28512625 )
2017
43
p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients. ( 26915336 )
2016
44
Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature. ( 26998168 )
2016
45
Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma. ( 26764222 )
2016
46
Angioimmunoblastic T-cell lymphoma mimicking dermatomyositis. ( 26898515 )
2016
47
Angioimmunoblastic T Cell Lymphoma Mimicking Chronic Urticaria. ( 26925107 )
2016
48
Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma. ( 27226129 )
2016
49
Expression of the significance of silent information regulator type-1 in Angioimmunoblastic T-cell lymphoma is greater association with tumorigenesis and has strong implications for adverse prognosis. ( 27124741 )
2016
50
BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. ( 27921272 )
2016
Sources

Variations for Angioimmunoblastic T-Cell Lymphoma

About this section

Cosmic variations for Angioimmunoblastic T-Cell Lymphoma:

9
(show top 50) (show all 146)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6498677 WDFY3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5163A>T p.L1721F 4:84765835-84765835 4
2 COSM6987215 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1625C>T p.P542L 16:2065544-2065544 4
3 COSM35978 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.811C>T p.R271* 6:137877081-137877081 4
4 COSM6498674 TLR6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1828G>T p.D610Y 4:38827646-38827646 4
5 COSM6933803 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4075C>A p.R1359S 4:105269640-105269640 4
6 COSM42037 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4210C>T p.R1404* 4:105272591-105272591 4
7 COSM211617 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3061C>T p.Q1021* 4:105237003-105237003 4
8 COSM41741 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5618T>C p.I1873T 4:105276128-105276128 4
9 COSM5945065 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4553C>G p.S1518* 4:105275063-105275063 4
10 COSM87108 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2692G>T p.G898* 4:105236634-105236634 4
11 COSM4766169 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3500G>A p.R1167K 4:105241429-105241429 4
12 COSM6023745 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4707C>A p.Y1569* 4:105275217-105275217 4
13 COSM6023746 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3873G>A p.W1291* 4:105259688-105259688 4
14 COSM100058 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4333C>T p.Q1445* 4:105272714-105272714 4
15 COSM6023743 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5636A>G p.E1879G 4:105276146-105276146 4
16 COSM4766127 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4133G>T p.C1378F 4:105269698-105269698 4
17 COSM4383952 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4519C>T p.Q1507* 4:105272900-105272900 4
18 COSM5945026 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2233C>T p.Q745* 4:105236175-105236175 4
19 COSM6987361 SPEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.6073G>T p.E2025* 1:15932313-15932313 4
20 COSM1161155 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4G>A p.V2I 16:11255475-11255475 4
21 COSM6987240 RET haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1759+1G>A p.? 10:43112964-43112964 4
22 COSM6987362 REL haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1077C>A p.Y359* 2:60920632-60920632 4
23 COSM6953464 PTPRT haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2353C>T p.L785F 20:42248703-42248703 4
24 COSM6023748 PLCG1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2606G>A p.G869E 20:41169482-41169482 4
25 COSM3734685 PLCG1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1034C>T p.S345F 20:41163944-41163944 4
26 COSM6916422 PIK3CG haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.220G>A p.V74M 7:106867781-106867781 4
27 COSM6987217 PAK5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1325C>A p.P442Q 20:9566050-9566050 4
28 COSM6498705 MIA3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5540C>A p.S1847* 1:222665435-222665435 4
29 COSM6987219 MED12 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4027C>A p.R1343S 23:71130194-71130194 4
30 COSM6498681 MDN1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1090G>T p.D364Y 6:89790167-89790167 4
31 COSM4169978 JAK1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3290G>A p.G1097D 1:64835475-64835475 4
32 COSM6498672 IFNAR2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.162G>A p.W54* 21:33245015-33245015 4
33 COSM33732 IDH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.515G>T p.R172M 15:90088606-90088606 4
34 COSM33731 IDH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.514A>G p.R172G 15:90088607-90088607 4
35 COSM33733 IDH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.515G>A p.R172K 15:90088606-90088606 4
36 COSM6987363 HIST1H3D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.383C>G p.A128G 6:26196868-26196868 4
37 COSM6987238 FAT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3463G>T p.D1155Y 4:186663416-186663416 4
38 COSM6987239 FAT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3463G>T p.D1155Y 4:186663416-186663416 4
39 COSM6987130 EGFR haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1939G>A p.A647T 7:55173002-55173002 4
40 COSM6498699 DYRK3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1288G>T p.V430L 1:206648591-206648591 4
41 COSM1304319 DOT1L haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2710G>A p.V904M 19:2220126-2220126 4
42 COSM6498709 DOCK10 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2701C>T p.P901S 2:224840027-224840027 4
43 COSM52944 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2645G>A p.R882H 2:25234373-25234373 4
44 COSM53042 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2644C>T p.R882C 2:25234374-25234374 4
45 COSM2911783 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1555-2A>G p.? 2:25244654-25244654 4
46 COSM6938921 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1279+1G>A p.? 2:25246619-25246619 4
47 COSM6987091 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.745C>T p.Q249* 2:25248147-25248147 4
48 COSM5944905 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2401A>G p.M801V 2:25239137-25239137 4
49 COSM4383603 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.915G>A p.W305* 2:25247690-25247690 4
50 COSM6498696 DHX9 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1885G>C p.E629Q 1:182876119-182876119 4
Sources

Expression for Angioimmunoblastic T-Cell Lymphoma

About this section
Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.
Sources

Pathways for Angioimmunoblastic T-Cell Lymphoma

About this section

Pathways related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MECP2 and Associated Rett Syndrome 1
10.95 BCL6 TET2
2
B Cell Development Pathways 65
10.68 BCL6 MME
3
Cytosine methylation 1
Show member pathways
 9.74 IDH2 TET2
Sources

GO Terms for Angioimmunoblastic T-Cell Lymphoma

About this section

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.33 BCL6 CXCL13 ITK
2 cytokine production GO:0001816 8.96 ITK MAF
3 germinal center formation GO:0002467 8.62 BCL6 CXCL13
Sources

Sources for Angioimmunoblastic T-Cell Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....